Alvotech
NASDAQ:ALVODrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $1.62B
- Beta
- 0.21
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.24
Volume 1.56M
Average 0.65M
ALVO Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
AlvotechNASDAQ: ALVO
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit declines year over year
Q1 FY2026 gross profit of $59.78M fell 11.2% year over year, behind the -3.3% change in trailing-twelve-month gross profit. Sequentially, it fell 43.1% from the prior quarter. Over 3 fiscal years it compounded at +164.6% a year.
Context
- Gross profit amounted to 59.8% of revenue in FY2025, down 2.3 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -11.2% toward the trailing-twelve-month pace of -3.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 350.76M USD
- Year-over-year change
- +15.2%
- 4-year CAGR
- +75.7%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 350.76M | +15.2% |
| FY2024 | 2024-12-31 | 304.37M | +538.4% |
| FY2023 | 2023-12-31 | (69.42M) | -466.7% |
| FY2022 | 2022-12-31 | 18.93M | -48.5% |
| FY2021 | 2021-12-31 | 36.77M | — |
Gross Profit vs competitors
How ALVO compares with its peers on the latest reported figures
- ALVO's LTM Mar 2026 gross profit of $343.22M is the 8th highest of the 11 companies compared; the peer median is $2.24B.
- Its year-over-year change of -3.3% is the 8th highest of 11, against a peer median of +12.1%.
- Gross profit amounts to 61.4% of revenue for ALVO, versus a peer median of 57.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $27.7B | +23.1% | +9.3% | 72.7% | |
| LTM Jun 2026 | $13.18B | +8.4% | +5.4% | 84.9% | |
| LTM Jun 2026 | $9.09B | +10.2% | +8.6% | 52.5% | |
| LTM Jun 2026 | $6.74B | -7.1% | -4.3% | 67.7% | |
| LTM Sep 2026 | $3.26B | -6.1% | -4.7% | 53.4% | |
| LTM Jun 2026 | $1.23B | +14.1% | +12.8% | 39.3% | |
| LTM Mar 2026 | $483.18M | +26.1% | +30.3% | 60.7% | |
| LTM Mar 2026 | $343.22M | -3.3% | +164.6% | 61.4% | |
| LTM Mar 2026 | $341.13M | -7.6% | +12.7% | 47.3% | |
| LTM Mar 2026 | $199.11M | +25.5% | +47.9% | 74.1% | |
| LTM Mar 2026 | $47.61M | +68.5% | +44.0% | 54.8% | |
| Peer median (excluding ALVO) | $2.24B | +12.1% | +11.0% | 57.7% | |
Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 36.77M | 83.03M | 91.43M | 489.68M | 586.32M |
| Cost of Revenue | 0 | 64.1M | 160.86M | 185.31M | 235.56M |
| Gross Profit | 36.77M | 18.93M | (69.42M) | 304.37M | 350.76M |
| Gross Margin | 100.0% | 22.8% | -75.9% | 62.2% | 59.8% |
| Research & Development | 191.01M | 180.62M | 210.83M | 171.31M | 184.19M |
| Selling, General & Admin | 84.13M | 186.74M | 73.04M | 61.45M | 90.95M |
| Operating Expenses | 272.23M | 365.38M | 285.44M | 234.73M | 272.56M |
| Depreciation & Amortization | 18.2M | 20.41M | 24.21M | 31.3M | 37.85M |
| EBITDA | (18.03M) | (439.8M) | (493.67M) | (32.28M) | 323.39M |
| EBITDA Margin | -49.0% | -529.7% | -539.9% | -6.6% | 55.2% |
| Operating Income | (235.46M) | (346.44M) | (354.86M) | 69.64M | 78.21M |
| Operating Margin | -640.3% | -417.3% | -388.1% | 14.2% | 13.3% |
| Interest Income | 19K | 912K | 4.82M | 4.62M | 198.49M |
| Interest Expense | 112.97M | 91.44M | 134.82M | 157.6M | 149.19M |
| Other Income / Expenses | 86.26M | (205.21M) | (296.19M) | (287.21M) | 58.14M |
| Income Before Tax | (149.2M) | (551.65M) | (651.05M) | (217.56M) | 136.35M |
| Pre-Tax Margin | -405.7% | -664.4% | -712.0% | -44.4% | 23.3% |
| Income Tax Expense | (47.69M) | (38.07M) | (99.32M) | 14.3M | 108.43M |
| Net Income | (101.5M) | (513.58M) | (551.73M) | (231.86M) | 27.92M |
| Net Margin | -276.0% | -618.6% | -603.4% | -47.3% | 4.8% |
| EPS (Basic) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| EPS (Diluted) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| Weighted Avg Shares | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
Alvotech
NASDAQ:ALVO
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.